Correction: Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation Correction: After Resuscitation-2 (RADAR-2) randomised clinical trial

Affiliations

• ¹ Department of Critical Care, Belfast Health and Social Care Trust, Belfast, UK. j.silversides@qub.ac.uk.
• ² Wellcome-Wolfson Institute for Experimental Medicine, Queen's University of Belfast, Lisburn Road, Belfast, BT9 7BL, UK. j.silversides@qub.ac.uk.
• ³ Department of Critical Care, Belfast Health and Social Care Trust, Belfast, UK.
• ⁴ School of Health Sciences, City, University of London, London, UK.
• ⁵ Independent Consulting Statistician, Aviemore, UK.
• ⁶ Department of Critical Care, Manchester University NHS Foundation Trust, Manchester, UK.
• ⁷ Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
• ⁸ Critical Care Directorate, Aneurin Bevan University Health Board, Newport, UK.
• ⁹ Department of Anaesthesia, Intensive Care and Pain Medicine, Cardiff University, Cardiff, UK.
• ¹⁰ Intensive Care Unit, South-Eastern Health and Social Care Trust, Dundonald, UK.
• ¹¹ Integrated Critical Care Unit, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
• ¹² Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
• ¹³ Intensive Care Unit, Northern Health and Social Care Trust, Antrim, UK.
• ¹⁴ Wellcome-Wolfson Institute for Experimental Medicine, Queen's University of Belfast, Lisburn Road, Belfast, BT9 7BL, UK.
• ¹⁵ Keenan Research Centre for Biomedical Science, Unity Health Toronto, Toronto, Canada.
• ¹⁶ Interdepartmental Division of Critical Care, University of Toronto, Toronto, Canada.